Sandra Vázquez-Reyes

Sandra Vázquez-Reyes

Auto-generated profile, based on publicly available information

Sandra Vázquez-Reyes

Cardiovascular Risk Factors and Brain Health Programme, Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain (F.J.D.C.-M., S.V.-R., C.P.-M., A.R.-L., C.P.-P., C.N.-V., A.G.-C., M.I.C., M.A.M.).

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2025 in Stroke
Verified
Journal Article
Open access
GDGaohong Di
Gaohong Di
SVSandra Vázquez-Reyes
Sandra Vázquez-Reyes
BBBlanca Díaz Benito
Blanca Díaz Benito
CPCarolina Peña-Martinez
Carolina Peña-Martinez
AGAlicia García-Culebras
Alicia García-Culebras
ILIgnacio Lizasoain
Ignacio Lizasoain
BACKGROUND: Acute ischemic stroke treatment typically involves tissue-type plasminogen activator (tPA) or tenecteplase, but about 50% of patients do not achieve successful reperfusion. The causes of tPA resistance, influenced by thrombus composition and timing, are not fully clear. Neutrophil extracellular traps (NETs), associated with poor outcomes and reperfusion resistance, contribute to thrombosis. DNase-I, which degrades neutrophil extracellular traps, could improve thrombolytic efficacy. However, more studies are needed to understand the impact of DNase-I in tPA-sensitive stroke models, the safety of coadministering DNase-I and tPA regarding hemorrhagic transformation (HT), optimal timing for use, and effects on aspirin-treated animals. METHODS: We used in situ thromboembolic stroke, a tPA-sensitive model, where late tPA administration causes HT. Middle cerebral artery occlusion was induced at different zeitgeber times (ZT) to study the optimal timing for administration. DNase-I, tPA, and aspirin were administered at various times to evaluate their effects. RESULTS: DNase-I reduced infarct volume and improved functional outcomes 24 hours post-middle cerebral artery occlusion by decreasing plasma and cortical neutrophil extracellular trap levels. DNase-I caused no bleeding or impact on HT induced by late tPA. Its protective effect was only seen when given during the daytime (rodent inactive phase; ZT4–7), not overnight (active phase; ZT13–16). Chronic aspirin pretreatment increased tPA-induced HT but did not change the protective effects of DNase-I, with or without tPA. CONCLUSIONS: Our study demonstrates that daytime (inactive phase) DNase-I administration is a safe and effective treatment for experimental stroke. This is particularly important given the 2 ongoing clinical trials for stroke patients. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT05203224 and NCT05880524.

1 October 2023 in Stroke
Verified
Journal Article
Closed access
CTCristina Torres-López
Cristina Torres-López
MCMaria I. Cuartero
Maria I. Cuartero
AGAlicia García-Culebras
Alicia García-Culebras
JPJuan de la Parra
Juan de la Parra
MFMaría Encarnación Fernández-Valle
María Encarnación Fernández-Valle
MMMaría A. Moro
María A. Moro
BACKGROUND: Cognitive dysfunction is a frequent stroke sequela, but its pathogenesis and treatment remain unresolved. Involvement of aberrant hippocampal neurogenesis and maladaptive circuitry remodeling has been proposed, but their mechanisms are unknown. Our aim was to evaluate potential underlying molecular/cellular events implicated. METHODS: Stroke was induced by permanent occlusion of the middle cerebral artery occlusion in 2-month-old C57BL/6 male mice. Hippocampal metabolites/neurotransmitters were analyzed longitudinally by in vivo magnetic resonance spectroscopy. Cognitive function was evaluated with the contextual fear conditioning test. Microglia, astrocytes, neuroblasts, interneurons, γ-aminobutyric acid (GABA), and c-fos were analyzed by immunofluorescence. RESULTS: Approximately 50% of mice exhibited progressive post–middle cerebral artery occlusion cognitive impairment. Notably, immature hippocampal neurons in the impaired group displayed more severe aberrant phenotypes than those from the nonimpaired group. Using magnetic resonance spectroscopy, significant bilateral changes in hippocampal metabolites, such as myo-inositol or N-acetylaspartic acid, were found that correlated, respectively, with numbers of glia and immature neuroblasts in the ischemic group. Importantly, some metabolites were specifically altered in the ipsilateral hippocampus suggesting its involvement in aberrant hippocampal neurogenesis and remodeling processes. Specifically, middle cerebral artery occlusion animals with higher hippocampal GABA levels displayed worse cognitive outcome. Implication of GABA in this setting was supported by the amelioration of ischemia-induced memory deficits and aberrant hippocampal neurogenesis after blocking pharmacologically GABAergic neurotransmission, an intervention which was ineffective when neurogenesis was inhibited. These data suggest that GABA exerts its detrimental effect, at least partly, by affecting morphology and integration of newborn neurons into the hippocampal circuits. CONCLUSIONS: Hippocampal GABAergic neurotransmission could be considered a novel diagnostic and therapeutic target for poststroke cognitive impairment.

16 January 2026 in Circulation Research
Verified
Journal Article
Open access
SVSandra Vázquez-Reyes
Sandra Vázquez-Reyes
AGAlicia García-Culebras
Alicia García-Culebras
GDGaohong Di
Gaohong Di
FCFrancisco J. De Castro-Millán
Francisco J. De Castro-Millán
BBBlanca Díaz Benito
Blanca Díaz Benito
MMMaría Ángeles Moro
María Ángeles Moro
BACKGROUND: Stroke remains a leading cause of mortality and disability, driven by complex, time-dependent mechanisms that aggravate ischemic injury. Collateral perfusion dictates infarct size, expansion rate, and penumbral preservation, yet its regulation is poorly understood. Beyond structural/genetic factors such as aging or cardiovascular risk, functional influences like circadian immune activity may also affect vascular patency. Neutrophils, key mediators of ischemic injury, exhibit circadian oscillations in phenotype and function that could modulate collateral flow and stroke outcome. METHODS: We combined permanent and transient middle cerebral artery occlusion models in mice with flow cytometry, single-cell RNA sequencing, confocal microscopy, and laser speckle imaging to investigate time-of-day–dependent neutrophil mechanisms in stroke. Pharmacological (chloramidine, DNase-I) and genetic (Pad4 [peptidyl arginine deiminase 4] −/ − , Bmal1 [brain and muscle ARNT (aryl hydrocarbon receptor nuclear translocator)-like 1] Neu , Cxcr4 [C-X-C chemokine receptor type 4] Neu ) interventions were used to define how time-of-day regulation shapes neutrophil function, neutrophil extracellular traps (NETs) formation, and stroke severity. A cohort of 540 patients with ischemic stroke was analyzed for diurnal patterns of NET-related biomarkers and their association with collateral circulation and clinical outcomes. RESULTS: Infarct volume and neurological deficits exhibited clear circadian oscillations, with worse outcomes when stroke occurred during the murine inactive phase (Zeitgeber time 5) versus the active phase (Zeitgeber time 13). These fluctuations disappeared after neutrophil depletion or clock disruption. During the inactive phase, neutrophils displayed an activated, NET-prone phenotype, causing microvascular stalling and reduced collateral perfusion. Inhibiting NET formation pharmacologically or through Pad4 deletion restored perfusion and abolished time-of-day effects. In patients, neutrophil and NET-related biomarkers (MPO [myeloperoxidase], elastase, sCD40L [soluble CD40 ligand]) showed diurnal oscillations, peaking during the human inactive phase (evening/night), coinciding with reduced collateral flow and poorer outcomes. CONCLUSIONS: Time-of-day regulation of neutrophil function critically determines collateral perfusion and stroke severity. Neutrophil-driven NETosis during the inactive phase promotes microvascular obstruction and worsens outcomes. Targeting NET formation or timing therapy could enhance collateral efficacy and offer novel chronotherapeutic opportunities for stroke treatment.

1 July 2026 in Stroke
Verified
Journal Article
Closed access
SVSandra Vázquez-Reyes
Sandra Vázquez-Reyes
Elga EspositoElga Esposito
Elga Esposito
ARAnna Rosell
Anna Rosell
ILIgnacio Lizasoain
Ignacio Lizasoain
ELEng Lo
Eng Lo
Kazuhide HayakawaKazuhide Hayakawa
Kazuhide Hayakawa
The central nervous system was once viewed as immunologically privileged, but it is now recognized that brain-immune interactions are dynamic and critical. After central nervous system injury or disease, microglia and perivascular macrophages survey the damaged tissue, while diverse immune cells infiltrate through various barriers, driving neurovascular dysfunction and neuroinflammation. Depending on timing and phenotype, systemic immune responses can also promote brain repair and recovery. Recent studies show that brain-peripheral organ communication profoundly affects both injury progression and healing. These insights redefine the neurovascular-immune interface and the concept of the brain’s immune system. This review examines immune cell infiltration and highlights emerging brain-peripheral circuits that regulate neuroinflammation and recovery after stroke.

1 September 2026 in Stroke
Verified
Journal Article
Open access
FCFrancisco J. De Castro-Millán
Francisco J. De Castro-Millán
SVSandra Vázquez-Reyes
Sandra Vázquez-Reyes
CPCarolina Peña-Martínez
Carolina Peña-Martínez
ARAdrián Rodríguez-Llave
Adrián Rodríguez-Llave
CPCarlos Parra-Pérez
Carlos Parra-Pérez
MMMaría Ángeles Moro
María Ángeles Moro
BACKGROUND: Adult hippocampal neurogenesis is altered after cerebral ischemia. Although stroke increases newborn neuron production, many cells display aberrant morphological and positional features that may impair functional integration and contribute to long-term cognitive deficits. Given the clinical heterogeneity of ischemic stroke and limited translational success of preclinical studies relying on single models, it remains unclear whether poststroke neurogenic alterations are conserved across experimental paradigms. This study aimed to identify common and model-specific features of hippocampal neurogenesis across focal ischemia models. METHODS: We conducted a multicenter, multimodel analysis within the Leducq-funded Stroke-Impact Transatlantic Network of Excellence using permanent and transient middle cerebral artery occlusion paradigms, including distal middle cerebral artery occlusion under normoxic or hypoxic conditions (distal middle cerebral artery occlusion+hypoxia), and filament-based transient middle cerebral artery occlusion, across 6 sites. Adult C57BL/6J mice were analyzed at 3 days, 7 days, and 2 months after ischemia, sham, or naïve conditions. Hippocampal proliferation (Ki67) and neuroblasts (DCX [doublecortin]) were quantified; morphological maturation of newborn neurons was assessed through high-resolution analyses of dendritic architecture and somatodendritic polarity. RESULTS: Across all stroke models, ischemia induced a robust bilateral increase in hippocampal proliferation, most pronounced at 3 days and still elevated at 7 days, returning to baseline by 2 months. Neuroblast density was similarly increased at 7 days, particularly in the ipsilateral hippocampus, but normalized over time. Despite recovery in cell number, long-term analyses revealed a consistent reduction in apical dendrite length and increased proportion of neurons with aberrant features, including ectopic positioning, polarity defects, and abnormal lateral growth, across models and centers. CONCLUSIONS: Aberrant hippocampal neurogenesis represents a robust hallmark of poststroke pathology in mice, independent of ischemia type or surgical approach, despite known differences in the spatial distribution of primary injury across models. Our findings underscore the importance of considering structural quality, and not only quantity, of newborn neurons when evaluating poststroke plasticity and developing therapeutic strategies.

22 February 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
FCFrancisco J. De Castro-Millán
Francisco J. De Castro-Millán
SVSandra Vázquez-Reyes
Sandra Vázquez-Reyes
CPCarolina Peña-Martínez
Carolina Peña-Martínez
ARAdrián Rodríguez-Llave
Adrián Rodríguez-Llave
CPCarlos Parra-Pérez
Carlos Parra-Pérez
MMMaría Ángeles Moro
María Ángeles Moro
Background: Adult hippocampal neurogenesis is markedly altered after cerebral ischemia. Although stroke increases the production of newborn neurons, many of these cells display aberrant morphological and positional features that impair their functional integration and contribute to long-term cognitive decline. Given the clinical heterogeneity of ischemic stroke and the persistent translational failures of preclinical approaches relying on single-model studies it remains unknown whether post-stroke neurogenic alterations are conserved across different experimental paradigms. This study aimed to define common and model-specific features of hippocampal neurogenesis across complementary focal ischemia models. Methods: We performed a multi-center, multimodel analysis within the STROKE-IMPaCT consortium using permanent and transient middle cerebral artery occlusion (MCAO) paradigms (MCAO via ligation or cauterization under normoxic (dMCAO) or hypoxic conditions (dMCAO+Hypoxia); and filament-based tMCAO across six international sites. Brains from adult C57BL/6J mice were collected 3 days, 7 days, or 2 months after ischemia, sham, or naive conditions. Hippocampal cell proliferation (Ki67) and neuroblast density (DCX) were quantified, and the morphological maturation of newborn neurons was evaluated using high-resolution analyses of dendritic architecture and somatodendritic polarity. All analyses were performed blind to experimental group. Results: Across all stroke models, ischemia induced a robust bilateral increase in hippocampal cell proliferation, most pronounced at 3 days and still elevated at 7 days, with levels returning to baseline by 2 months. Neuroblast density was similarly increased at 7 days, particularly in the ipsilateral hippocampus, but normalized by 2 months. Despite recovery in cell number, long-term morphological analysis revealed a consistent reduction in apical dendrite length and a higher proportion of neurons exhibiting aberrant features including ectopic localization, multipolar or inverted polarity, and abnormal lateral growth across all models. These abnormalities were observed both when pooling data across sites and when analyzing each model or center individually. Conclusions: Ischemia induces an early, transient increase in hippocampal neurogenesis across diverse stroke paradigms, but the newborn neurons generated after stroke consistently display maladaptive morphological features. These cross-model, cross-site abnormalities indicate that aberrant hippocampal neurogenesis represents a robust hallmark of post-stroke pathology within the investigated species, independent of ischemia type or surgical approach, despite known differences in the spatial distribution of primary injury across experimental stroke models. Our findings support the concept that maladaptive neurogenesis may contribute to chronic post-stroke cognitive impairment and underscore the need to consider the quality not only the quantity of newborn neurons when developing therapeutic strategies.